Skip to content

Development of a novel method to prevent cognitive decline using a "healing smart space" that stimulates the five senses

A novel strategy for prevention of cognitive decline and stress care using a "smart healing space" that stimulates the five senses - An integrative medical approach based on co-creation between humans and the latest technology - A novel strategy for prevention of cognitive decline and stress care using a "healing smart space" that stimulates the five senses

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000046310
Enrollment
60
Registered
2021-12-07
Start date
2021-12-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment, behavior and psychological symptoms of dementia, stress

Interventions

The intervention group will perform reminiscence using the Healing Smart Space once a week for 3 months, and subjective and objective assessments will be conducted. Subjective assessments will include

Sponsors

Osaka Center for Cancer and Cardiovascular Disease Prevention
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1.20 years of age or older 2.A client of the Misasagikai Elderly Care Center 3.MMSE-J score of 16 or higher 4.Have not started using donepezil, rivastigmine, galantamine, or memantine within the last 3 months. 5.Consent will be obtained from the individual to participate in this study.

Exclusion criteria

Exclusion criteria: 1.Under 20 years old. 2.MMSE-J score of 15 or less. 3.Have a visual impairment that prevents recognition of images even when vision is corrected with glasses, etc. 4.Have hearing impairment to the extent that they cannot hear sounds even with the use of hearing aids. 5.Self-reported susceptibility to motion sickness or VIMS. 6.Has difficulty in sitting up. 7.Cognitive function has declined to the extent that the patient is unable to answer the questionnaire (e.g., communication is not possible even with support when answering). 8.Has started donepezil, rivastigmine, galantamine, or memantine within the last 3 months. 9.Is judged by the principal investigator to be inappropriate for participation in this study.

Design outcomes

Primary

MeasureTime frame
Change in the Japanese version of the Montreal Cognitive Assessment (MoCA-J) between baseline and post-intervention

Countries

Japan

Contacts

Public ContactToshinori Ito

Osaka Center for Cancer and Cardiovascular Disease Prevention head of an office

juki@osaka-ganjun.jp06-6969-6711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026